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Due to research advances in vascular biology, as-
sessment of the vasculature as a conduit for circu-
lating blood has been successively revisited during
the past century. At present, the vasculature is
known as a complex organ, capable of synthesizing
and secreting a wide variety of biological me-
diators and responding to numerous chemical and
mechanical signals. Obstructive vascular disease,
mainly atherosclerosis, can disturb these functions
and cause serious clinical symptoms (42, 169, 170).
Diagnostic and therapeutic options have
changed substantially during recent decades. Inter-
ventional treatment methods such as percutaneous
transluminal angioplasty (PTA) and insertion of
vascular metallic endoprosthesesª stents (32, 37,
39, 57, 77, 106, 110, 145, 172)ªhave in many cases
replaced traditional vascular surgery. However,
PTA and/or the insertion of stents also causes in-
jury to the vessel wall, followed by a healing pro-
cess (48, 50, 101, 106, 165, 189). This reparative
process can result in restenosis, caused by intimal
hyperplasia (IH) and a remodeling of the artery,
also called chronic spasm (128, 154, 155, 221). Sig-
nificant restenosis develops in 20–50% of treated
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vessels, impairing the long-term result of treatment
(60, 63, 91, 93, 94, 139, 175, 197). The restenosis
can cause recurrence of symptoms, with serious
consequences for the patient (99, 220).
The severity and the location of the atheroscler-
otic lesion are important factors for the outcome
of interventional treatment. Development of reste-
nosis is more frequent after treatment of long sten-
oses and of occlusions, while best results are ob-
tained after treatment of short stenoses (78, 87,
106, 119, 133, 219). The lumen diameter of the
treated artery is also important and is generally
inversely proportional to the frequency of signifi-
cant restenosis (78, 93). Several components from
the circulating blood and the artery wall are in-
volved in a complicated course of events following
PTA and stenting. Some of these events are of par-
ticular importance for the development of reste-
nosis (101). Different approaches to preventing re-
stenosis have been evaluated in experimental and
clinical studies and the results are reported in nu-
merous publications. Effects, results and con-
clusions presented below are most often based on
experimental animal studies; thus evaluation is dif-
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ficult or impossible in the human arteries. The
course of events can, to some extent, be different
in the atherosclerotic human arteries.
Effects of PTA
The aim of PTA is a restoration of the vessel lumen
and normalization of the blood flow. The dilation
balloon, used for PTA, is commonly longer than
the stenosis, to avoid its dislodgment during in-
flation. Consequently, both a stenotic segment of
the artery and also a normal arteryªadjacent to
the stenosis ªare dilated (62). The entire dilated
segment is denuded of endothelium and about 20%
of the smooth muscle cells (SMCs) in the media
are damaged (42, 52, 64, 101, 130, 159). The cir-
cumferential stretching of the artery wall can cause
disruption of the internal elastic membrane, and
also of the media (27, 64). Originating from the
plaque, intimal dissection can occur (64), and the
severity of the injury correlates to the degree of the
subsequent IH (85, 88). The atherosclerotic plaque
intrudes into the wall of the artery, but can also
fracture. Following PTA, several of the molecules
described below are released (79), activating circu-
lating blood components and cells in the vessel
wall, and starting a process of repair (Figure).
Blood components: Following deflation of the an-
gioplasty balloon, platelets adhere and aggregate
to the endothelium-denuded subendothelial ma-
trix, and fibrin is also deposited in the damaged
area (101). Platelets secrete procoagulants, pro-
moting further development of the thrombus, but
also several others mediators (170). Two of these
mediators ª the platelet-derived growth factor
Figure. Some of the most important oc-
currences after PTA.
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(PDGF) and the transforming growth factor b
(TGF b)ªhave important roles in the develop-
ment of IH. The PDGF stimulates migration of
the SMCs to the intima (91, 92, 134, 137) and the
TGF b stimulates SMCs to synthesize extracellular
matrix components (42).
Leukocytes entering the damaged portion of the
artery promote the inflammatory response and can
contribute to the formation of IH (166, 200). In
the intima, monocytes are transformed to macro-
phages (69), which besides phagocytosis can secret
TGF b, endothelial mitogens, and also factors in-
hibiting endothelial cell growth. Activated by PTA,
neutrophils aggregate in the damaged area, and
can contribute to damage of the peripheral tissues
during reperfusion following angioplasty (123,
147). Leukocytes can also secrete growth factors,
oncogenes and attractants stimulating further
colonization of the vessel wall by macrophages.
Intima: In the normal artery the intima consists
of a single layer of partly overlapping endothelial
cells, creating a smooth, non-thrombogenic and
non-adherent surface. Endothelial cells build up a
permeable barrier to the deeper layers of the ar-
terial wall and have a key role in the regulation
of normal vascular function (33, 71, 138, 150). In
response to mechanical stimuli and to circulating
vasoactive substances, the endothelium regulates
vascular tonus via several biological mediators.
One of these mediators, the endothelium-derived
relaxing factor (EDRF), causes relaxation of the
artery, and inhibits proliferation of SMCs. Several
investigators have suggested that EDRF is the ni-
tric oxide (NO) molecule, or that NO is the active
part of EDRF (42, 127). The vasorelaxant NO also
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stimulates endothelial cell growth and inhibits ag-
gregation of platelets (42, 46).
Endothelium-derived prostacyclin is another po-
tent platelet antiaggregator (33). In contrast, the
potent, endothelium-derived vasoconstrictors
angiotensin II and endothelin stimulate prolifer-
ation of SMCs (73). The endothelium also synthes-
izes heparin and heparan sulfate, which, beside
their anticoagulant effect, also have an inhibitory
effect on SMC proliferation (42, 139). These ef-
fects are mediated by the different fractions of the
heparin molecule. Secreted by endothelial cells,
tissue plasminogen activator (TPA) and urokinase
plasmin activator prevent thrombus formation, but
can also participate in degradation of the extracel-
lular matrix, which is necessary for the migration
of the SMCs. Disruption of the internal elastic
lamina probably facilitates migration of the SMCs
to the intima; however, the SMC also migrates via
channels in the intact lamina.
Media: The contractile SMCs are responsible for
maintenance of vascular tonus. Injured SMC syn-
thesizes the basic fibroblast growth factor (b-
FGF), which stimulates transformation of these
cells to the synthetic, proliferative phenotype (44,
80, 92, 101, 108, 208). The b-FGF also promotes
endothelial regrowth (139). The extracellular ma-
trix, composed of collagen, elastic fibers and
proteoglycans, is affixed to the membranes of the
SMC. The SMC can secrete proteolytic enzymes,
which resolve these bindings and promote mi-
gration of the SMC cells to the intima (42, 130).
After arterial injury, proliferation of the SMCs can
be stimulated by other factors, such as the epider-
mal growth factor or Gbeta gamma (75, 86). The
SMCs are of the same phenotype as the fibroblasts
and are able to start the synthesis of extracellular
matrix (80), which in the intima forms a large part
of intimal hyperplasia.
Adventitia: The adventitia, divided from media
by the external elastic lamina, is responsible for the
nutritional support of the artery wall. Temporary
hyperemia after PTA and changes in the vasa vaso-
ra in the adventitia have been observed (42, 152,
153). It was suggested that changes in the adventit-
ia can contribute to the development of IH (11,
44).
Course of events after PTA: During and after
PTA, the vasoconstrictors endothelin and angio-
tensin II are released from endothelial cells and b-
FGF is simultaneously released from the injured
SMCs. These molecules contribute to the prolifer-
ative response of the SMCs (92, 206). As soon as
blood flow is restored, platelets and fibrin adhere
to the molecules presented at the denuded suben-
dothelial matrix (25). Platelets release PDGF,
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stimulating migration of the SMCs to the intima,
and TGF b stimulates the production of extracel-
lular matrix (22). The aggregation of platelets on
the surface can continue promoting thrombus for-
mation, but usually stops within hours. After 1day
the surface is no longer thrombogenic, probably
due to an overlying coat of plasma proteins (101).
A transient decrease in fibrinolytic activity in the
arterial wall can promote further building of the
thrombus (174). Monocytes, macrophages and
neutrophils accumulate in the injured part of the
artery, secreting mitogenic factors (69, 123). Pro-
liferation and migration of endothelial cells start
from the borders of the injured area and from ar-
terial side branches (200). About 50% of uninjured
SMC changes from the contractile phenotype to
the proliferative. DNA synthesis starts in prolifer-
ative SMCs within 48h (26, 92, 101, 118, 129).
SMCs and endothelial cells support lysis of the
extracellular matrix by the secretion of proteolytic
enzymes (101, 129).
Migration of the SMCs to the intima usually be-
gins 4–7days after PTA. Proliferation of SMCs
reaches a maximum after 7 days, subsequently de-
creases, and is practically terminated after 4 weeks
(18, 25, 189). At this time endothelialization of the
damaged area is also terminated (118). The new
endothelial cells are immature, with partly insuf-
ficient function (211, 218). Synthesis of the compo-
nents of the extracellular matrix by SMCs in the
intima continues for up to 3–6months (66, 101).
At this time extracellular matrix represents up to
80% of the volume of the neointima. During the
following year, partial regression of the IH may
occur in about 10% of cases (120, 124). After a few
years, the neointima changes form and resembles
an atherosclerotic plaque (25) with foam cells, col-
lagen, and calcifications. Whether this process is a
natural event, or represents recurrence of athero-
sclerosis, is unclear (216).
Recently, attention has also been focused on
chronic elastic recoil, another important factor
contributing to restenosis after PTA (60, 216). This
event has been observed during intravascular
ultrasonography (IVUS) examinations of human
coronary arteries and has also been investigated in
an experimental study (116).
Effects of stent insertion
A stent is usually used if the effect of PTA is unsat-
isfactory (68), but stents are also used for treat-
ment of arterial occlusion, dissection and reste-
nosis (14, 145, 158). The benefit of primary stent
treatment of arterial stenosis is still under dis-
cussion (203), but the clinical use of stents and
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their applications are still increasing (220). Differ-
ent stents have been developed and tested (3, 39,
40, 144, 145, 168, 196, 197) and new stents are be-
coming available. Stainless steel and nitinol are the
most common stent materials, but other metals
have also been used (39, 98, 110, 179, 197). Metal
implants cause mechanical and chemical irritation
(45) and gold-coating of stents, for example, has
caused a significant increase in IH (98, 179). Due
to the lack of comparative clinical studies, it is dif-
ficult to estimate the importance of the stent ma-
terial for long-term results. The development of IH
can be partly related to the type or construction of
the stent (12, 24, 41, 54) and to the number of
inserted stents (149).
On the basis of the delivery system, stents can be
divided into balloon-expandable and self-ex-
panding stents. The artery is balloon-dilated dur-
ing deployment of the balloon-expandable stent.
The balloon, which is always longer than the stent,
causes endothelial damage also outside the stent
(62). Self-expanding stents are inserted after PTA
and subsequently balloon-dilated (198). Thus,
PTA starts processes in the wall of an artery as
described above, but the stent has several ad-
ditional effects. The stent prevents vascular spasm
and elastic recoil and keeps the atherosclerotic
plaque and/or the intimal flap, in case of dissec-
tion, away from the lumen of the artery (145, 184).
The self-expanding stent can continue expanding
due to radial forces, which can also stimulate the
development of IH (112). The metallic stent can
disturb the electrostatic equilibrium (45) and in-
crease the number of platelets and neutrophils in
the treated part of the artery (147). Compared to
PTA the stent can also prolong disturbances to en-
dothelial function (211). Changes in vasa vasorum
were observed after stenting (152, 153, 188).
The elastic properties of the stent and the artery
are different, and the artery loses compliance after
stent insertion (7, 168). A relatively stiff stent can-
not follow the movement of surrounding tissues in
the body as the artery does. The temporarily com-
pressed and folded self-expanding stent can regain
its shape, whereas external forces can irreversibly
deform the balloon-expandable stent (4).
Course of events after stent insertion: The surface
of the metal implanted in the vessel will be covered
by a strongly adherent monolayer of proteins after
only 5s. After 1min, the surface is uniformly
coated by five layers of proteins, predominantly
fibrinogen (9). The holes between the stent wires
are filled with the thrombus, composed of fibrin,
platelets, and white and red blood cells (147, 163).
The amount of adherent platelets and leukocytes
increases during the first few hours after stent in-
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sertion (147, 160). The balloon-expandable stent
keeps the lumen of the artery open, stretching the
media. The self-expandable stent, which does not
expand to full diameter after insertion, can expand
further during the following days, progressively di-
lating the artery (30).
The primary response of the vessel wall is, how-
ever, caused by PTA and is similar to the events
described above, with proliferation and migration
of SMCs and formation of neointima (8). The
thrombus formed between the stent wires is suc-
cessive replaced by proliferating neointima. In ani-
mal studies the stent was covered by IH after 4
weeks (30, 214), but development of IH usually
stops after 6months. IH can cause restenosis in the
stent lumen and/or at the edges of the stent. Later
progress of IH has also been observed (4). Endo-
thelialization starts immediately after the pro-
cedure and will continue until the stent and the
stented part of the artery are covered by immature
endothelium, which takes approximately 3–4weeks
(97, 163, 190). A mild inflammatory reaction can
persist during this time (12). Side branches of the
artery that are covered by the stent usually remain
open (3). The stent prevents chronic elastic recoil,
but also causes progressive atrophy of the media, a
phenomenon which has been observed 3–6months
after insertion (174). Regression of atherosclerotic
plaques in stented arteries has been reported in
studies based on autopsy (64).
Prevention of IH
After PTA and stenting, a reparative process is
necessary to regain normal vessel function and
should not be eliminated completely. Prediction of
the severity of IH is currently not possible, but
would be very valuable, since 50–80% of patients
do not develop significant restenoses. Prevention
of IH is unnecessary for this group of patients.
Various strategies to prevent IH have been tested
in experimental animal studies, frequently with the
aim to reduce SMC migration and proliferation,
and to accelerate endothelialization (121). Experi-
ments have been performed in both healthy vessels
and in the ‘experimental atherosclerosis’ model,
used in animal studies, which develops over weeks
or months (24, 49, 113, 171, 172). The lesion is
histologically similar to the human atherosclerotic
lesion, which takes years to develop (113). Balloon
denudation of the artery wall, used in the experi-
mental atherosclerosis model, has been used by
other investigators for creation of ‘intimal hyper-
plasia’ (206). The single experimental atheroscler-
otic lesion was located in the artery of a healthy
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animal, with good inflow and distal outflow of the
blood. Use of a different experimental technique
in causing the injury can affect the outcome of the
study (125, 129, 176, 195).
Anatomic variations in the structure of the ves-
sels also play an important role (12, 139), and use
of different vessels in the same animal can contrib-
ute to diversity of the obtained results (36, 198).
The response to vascular injury varies between dif-
ferent species, e.g., dogs and pigs (36, 121, 183).
Numerous stent models have been used in different
studies (12, 13, 56, 74, 168, 171, 180, 196). It was
suggested that development of IH is dependent on
the shape of the stent (3, 12, 54, 58, 180), while the
diameter of the stent is less important (82). How-
ever, high inflation pressure during insertion of the
balloon-expandable stent may promote IH (81).
The results of pharmacological therapy can be
influenced by different dose/response effects in dif-
ferent species (122). Evaluation of the results of
PTA and stenting and of restenosis has been done
using angiography, ultrasonography and histo-
pathologic examinations, but all these methods
have their drawbacks. The introduction of IVUS
during the last decade made possible a more ade-
quate evaluation of the lumen and the arterial wall
in vivo (57, 82, 84, 116, 181, 212, 219, 222). How-
ever, placement of the IVUS catheter through a
severe stenosis or occlusion can be difficult. It is
also difficult or impossible to study most of the
events in the wall of the artery of patients treated
by PTA or stent insertion.
Most of events described above, and of methods
preventing intimal hyperplasia proposed below, are
based on animal studies. This could partly explain
why these methods are seldom beneficial in clinical
trials. Several of these methods are also relatively
complicated, and can have substantial adverse ef-
fects for the patient. However, different proposed
approaches to prevent IH are summarized below:
Diet is one of the most important factors in the
development of atherosclerosis and was shown to
have a role in the development of restenosis in an
animal study (191). Supplementation of the diet
with unsaturated fatty acids was tested in clinical
studies (35, 161), but the considerable disagree-
ment regarding the obtained results is representa-
tive of the problems meeting scientists working
with prevention of IH.
Pharmacological approaches: Several drugs, de-
livered systemically or locally, have been tested (6,
27, 101). Unacceptably high doses (157) or require-
ment for a long delivery time (102) for prevention
of IH do, however, exclude some of these drugs
from clinical use.
Anticoagulant therapy is commonly used during
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and after endovascular interventions. Heparin is
routinely injected prior to PTA and stent place-
ment to prevent early thrombus formation. Due to
the supposed thrombogenic properties of the stent,
an additional dose of heparin is often given after
stenting (16, 136, 160). Medication with ASA or
dipyridamole after intervention has been proposed
and experimental studies have demonstrated that
anticoagulant therapy reduces the risk of throm-
bosis and restenosis (6, 29, 43, 162, 172, 187). In
other clinical and experimental studies, a reduction
in the severity of lesions was observed, while the
frequency of restenosis was not influenced by anti-
coagulant treatment (49, 50, 59, 167, 182, 187, 221,
223). Prolonged administration of heparin had an
effect on IH in experimental studies. However,
heparin does not inhibit proliferation of SMC in
vitro (209), and has also been considered a possible
causal factor of stent thrombosis (100). Cilostazol,
a relatively new anti-platelet agent, showed prelim-
inarily promising effects on IH after stent insertion
(207, 224), but this effect could not be confirmed
in a larger group of patients (146). There is no ob-
vious evidence that prolonged systemic administra-
tion of anticoagulant therapy has any significant
effect on the development of intimal hyperplasia.
Following an arterial injury, angiotensin I is con-
verted by angiotensin-converting enzyme (ACE) to
angiotensin II ªa potent vasoconstrictor, stimulat-
ing proliferation of SMCs (169). ACE inhibitors
reduced IH in animal experiments, but clinical
evaluation could not confirm these findings (107,
156, 157).
The inhibition of calcium transportation
through the cell membrane can reduce prolifer-
ation of the cells. Inhibition of IH by calcium
channel blockers was tested successfully in animal
experiments, but these drugs had no obvious ef-
fects in clinical trials (139, 177).
Steroids should reduce the inflammatory reac-
tion in the artery after intervention. Systemic ad-
ministration of steroids to patients did not prevent
the development of IH (151), although local depo-
sition of steroids was reported to have a positive
effect on IH (132, 196).
Cholesterol is necessary for cell membrane syn-
thesis, and decreased cholesterol levels can reduce
proliferation of SMCs (61). However, a desirable
proliferation of endothelial cells can be reduced
simultaneously. Lovastatin reduces serum chol-
esterol, but supplementation with lovastatin had
no obvious effects on the development of IH (139).
Another lipid-lowering substance, probucol,
showed positive effects on the restenosis rate and
reduced IH in clinical and experimental studies
(90, 126, 164). The mechanism of action of probuc-
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ol is not known, but seems to be mediated by free
radicals.
The entry of cells into the proliferative cycle can
be reduced by angiopeptin, an analogue of
somatostatin. In an animal study, angiopeptin de-
creased IH in about 50% of cases (53). A poor clin-
ical effect of angiopeptin can be explained by a
mode of action that is different to that of somato-
statin (2).
The vasorelaxant NO has an inhibitory effect on
SMC proliferation. Promising results have been
achieved with methods increasing levels of NO (47,
127, 185, 213). NO is synthesized in the endothelial
cell by the enzyme nitric oxide synthetase from -
arginine. Administration of the NO precursor -
arginine markedly diminished the development of
IH (21, 34, 65, 111, 122, 201). NO also suppresses
the aggregation of platelets and promotes endo-
thelialization (67), but slow release of NO from
coated stents had no effect on the development of
IH (17). Neither did oral administration of an NO-
releasing drug have any effect on SMC prolifer-
ation (76).
Suppression of Naπ-Hπ exchange (102), inhi-
bition of remodeling of the artery (109), local de-
livery of ethanol (117), and administration of anti-
allergic drugs, pemirolast potassium (142), or taxol
(188), also showed promising results in preventing
intimal hyperplasia in experimental studies.
Local drug delivery from drug delivery balloons
and from coated stents has been tested experimen-
tally, with encouraging results. Anticoagulant and
antiinflammatory drugs, agents stimulating endo-
thelialization and inhibiting SMC proliferation, re-
ceptor antibodies and ethanol were tested (1, 5, 6,
17, 51, 95, 105, 109, 117, 131, 132, 148, 195). How-
ever, clinical randomized studies evaluating experi-
mental results have seldom been performed. A
multicenter clinical trial, comparing the local de-
livery of heparin to intraluminal administration,
showed that the method was safe, but did not have
any advantages regarding the development of IH
(222).
Biological technology methods for prevention of
IH: Research advances in biological technology
have opened possibilities to form molecules inter-
acting with components in the artery wall. Differ-
ent approaches have been tested in animal studies.
Attempts were made to reduce platelet adhesion
and aggregation by local delivery of the platelet
glycoprotein IIb/IIIa receptor antibody (1, 204,
205). Acceleration of reendothelialization was
stimulated by the delivery of a vascular endothelial
growth factor (5, 19, 210) or by blockage of the
matrix glycoprotein thrombospondin-1 (22).
Seeding of cultivated endothelial cells on the ar-
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tery wall (28) or on stents (38) has been tested.
However, cell seeding after PTA can be difficult in
the clinical situation. Preservation of undamaged
endothelial cells on the most important, inner sur-
face, of the stent seems to be as difficult as carrying
out PTA without damage to the endothelium.
Inhibition of degradation of the extracellular
matrix prevents migration of SMCs to the intima.
It can be achieved by blocking molecules involved
in such degradation (15), or by blocking integrins
ªcell-surface receptors of the SMCªwhich pre-
serve attachment of SMCs to the extracellular ma-
trix (21, 23, 36).
In another experimental study, blockage of
PDGF-b receptors by specific neutralizing anti-
bodies inhibited PDGF stimulation of SMC pro-
liferation (72). Epidermal growth factor receptor-
targeted cytotoxin had a similar effect (148).
Genetic therapy after vascular injury is a rela-
tively novel, interesting approach to prevent IH
(89, 185, 193, 194, 213). Introduction of genetic
information into SMCs made them sensitive to
treatment with antiviral drug (ganciclovir), result-
ing in the death of the dividing cells (141).
The vascular endothelial growth factor (VEGF),
a potent, endothelial cell-specific mitogen, has
been used to promote angiogenesis. Experiments
showed a clear therapeutic benefit after a single in-
jection of VEGF. Also the FGF can promote
angiogenesis (135, 199). Clinical trials will show if
therapeutic angiogenesis can replace interventional
or surgical treatment of patients with peripheral
obstruction (89).
The biological technology is a relatively new, but
rapidly growing, scientific area. Possible side ef-
fects and clinical importance of the developed mol-
ecules and specific substances must be carefully
evaluated.
Other methods: Sympathectomy is used in treat-
ment of patients with arterial occlusive disease,
with the aim of preventing vasoconstriction. Sym-
pathectomy also had an inhibitory effect on the
development of restenosis (104). This effect can be
secondary to prevention of remodeling of an artery
after PTA.
Suppression of IH can be achieved by reduction
of the number of proliferating SMCs in the vessel
wall. Thermal methods, photodynamic therapy,
external irradiation and brachytherapy have been
used (55, 62, 96, 103, 114–116, 143, 178, 186, 202,
215). Radioactive stents were also constructed
(179, 217). All these methods cause destruction of
the SMCs in the media, which are subsequently
replaced by fibrotic tissue. The beneficial effect of
brachytherapy on IH has been documented in clin-
ical studies (114, 115, 202). b-particle-emitting
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gold stents had, however, the opposite effect (179,
198). Due to relatively short follow-up, the long-
term effect of brachytherapy and irradiation from
radioactive stents is still unknown. The common
use of irradiation for prevention of IH is also con-
troversial, due to the practical problems, the costs
and the selection of patientsª restenosis occurs
only in 20–50% of treated arteries.
The coating of stents with fibrin may have a posi-
tive effect on the development of IH, the opposite
to coating with polyurethane (83). Stents covered
by an autologous graft (192) or synthetic material
can prevent IH in the lumen of the device. How-
ever, restenosis in the stent–graft lumen has been
observed (10). Development of IH at the edges of
surgical grafts is a well-known problem (20, 87),
and the problem for intraluminal stents–grafts
may be similar (106). The stent–graft will also
close arterial side-branches, decreasing the pos-
sibilities of development of collateral circulation.
The endothelium inhibits development of IH,
but preservation of endothelium in the treated seg-
ment of the artery is practically impossible during
PTA (70, 101). IH can be diminished by perivas-
cular implantation of endothelial cells (140), but
the practical clinical value of this experiment can
be questioned. Insertion of a self-expanding stent
without balloon dilation reduces injury to the en-
dothelial cells and SMCs, and decreases the num-
ber of proliferating SMCs (31, 70, 173). Hypotheti-
cally, self-expanding stents strong enough to dilate
a stenosis could be used without additional bal-
loon dilation instead of PTA, to diminish trau-
matic injury to the vessel wall and, consequently,
to reduce the development of IH.
Restenosis is commonly treated by a new PTA
and/or insertion of a stent. Retreatment increases
costs, carries the risk of complications and is
troublesome for the patient. The prevention of IH
is not possible today, but several promising alter-
natives are being tested. Increased knowledge
about processes within the vessel wall after PTA
and stent insertion, and further progress in re-
search, are essential for further improvement of the
results of interventional treatment.
Summary
Results of PTA and stent insertion are affected by
restenosis, which causes a recurrence of symptoms,
leading to a need for renewed treatment in a sub-
stantial number of patients. IH is the most import-
ant factor in the development of restenosis. Pro-
cesses within the vessel wall responsible for devel-
opment of IH, and different approaches to prevent
restenosis discussed in this review, are most often
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based on animal studies and a randomized clinical
testing is required. Despite substantial efforts by
scientists and clinicians, the problem of restenosis
cannot be solved today by a single, commonly
available, method and further research and techni-
cal development is necessary.
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